Exercise of Options and TVR

Renalytix plc 

("Renalytix" or the "Company") 

Exercise of Options and TVR

NEW YORK, 19 July, 2021 - Renalytix plc (AIM: RENX) announces that it has issued and allotted 5,000 ordinary shares of 0.25 pence each in the share capital of the Company ("Ordinary Shares") following an exercise of options on 19 July 2021. The exercise price was 585 pence per Ordinary Share.

Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 5,000 new Ordinary Shares to trading on AIM will become effective on, or around, 23 July 2021 ("Admission").

Total voting rights

Following Admission, the Company will have 72,229,786 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 72,229,786.

For further information, please contact: 

About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.¹ Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year, kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

¹ https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About KidneyIntelX

KidneyIntelX, is a first-of-kind, bioprognostic^TM platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.